Table 3 We observed that, as the incorporation size at hexon increased the VP/IP ratio also increased compared to the His6 vectors or unmodified Ad5 .
From: Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach
Modified Viruses | Viral Particle (VP) | Infectious Particles (IP) | VP/IP |
|---|---|---|---|
Ad5 | 4.58 × 1012vp/ml | 3 × 1011PFU/ml | 15.26 |
Ad/HVR2-His6 | 5 × 1012vp/ml | 3 × 1011PFU/ml | 14.7 |
Ad/HVR5-His6 | 5 × 1012vp/ml | 4 × 1011PFU/ml | 14.25 |
Ad/HVR2-33RGD-His6 | 4.7 × 1011vp/ml | 2 × 109PFU/ml | 236 |
Ad/HVR5-33RGD-His6 | 1.85 × 1012vp/ml | 1.58 × 109PFU/ml | 1,170 |
Ad/HVR5-43RGD-His6 | 2.35 × 1012vp/ml | 3.98 × 108PFU/ml | 5,940 |
Ad/HVR5-53RGD-His6 | 1.01 × 1012vp/ml | 1.25 × 109PFU/ml | 808 |